- |||||||||| Mifeprex (mifepristone) / Danco Laboratories
EXPLORING THE REPRODUCTIVE BLACK MARKET: FERTILITY MEDICATIONS ON THE DARK WEB (Anaheim Convention Center - 208A) - Aug 21, 2022 - Abstract #ASRM2022ASRM_526; Due to stigma, drug shortages, and high costs patients will continue to resort to illegal means of obtaining fertility medications despite significant risks of using drugs without a prescription (e.g., counterfeit, contamination, and presence of untested substances). IMPACT STATEMENT: Physicians should be aware of the increasing use of illicit online marketplaces to purchase prescription medications as a significant public health issue (e.g., drug misuse/abuse) as well the risks of serious health consequences including death due to substandard or falsified medical products.
- |||||||||| letrozole / Generic mfg., clomifene citrate / Generic mfg.
THE PREDICTIVE VALUE OF ANTI MULLERIAN HORMONE IN INTRAUTERINE INSEMINATION CYCLES (Anaheim Convention Center - 303CD) - Aug 21, 2022 - Abstract #ASRM2022ASRM_519; Yet, we demonstrated that there is no difference in ongoing pregnancy rates or clinical pregnancy loss rates among patients with varying levels of AMH in IUI cycles. While AMH is a useful tool to assess ovarian reserve, this study suggests that it should not be over-interpreted as a predictive tool for reproductive potential in IUI cycles.
- |||||||||| metformin / Generic mfg., letrozole / Generic mfg.
Journal: VNOTES FOR OVARIAN DRILLING: A NEW MINIMAL INVASIVE TECHNIQUE. (Pubmed Central) - Aug 17, 2022 Suture of the posterior vagina Ovarian drilling is a surgical treatment proposed after the failure of first-line treatment in polycystic ovary syndrome to obtain long-term spontaneous ovulations. The development of minimally invasive techniques such as vNOTES will highlight this treatment and allow it to be performed easily and with minimal adverse effects on patients, especially in these bariatric women for whom the vNOTES technique provides easier access to their pelvic cavity than abdominal laparoscopy.
- |||||||||| Reolysin (pelareorep) / Oncolytics, Andrus Reo
Trial termination: AWARE-1: A Window-of-opportunity Study of Pelareorep in Early Breast Cancer (clinicaltrials.gov) - Aug 15, 2022 P1, N=26, Terminated, Results can inform future evaluations of new ABC treatments that estimate the health economic impact of their adoption in Korea. Recruiting --> Terminated; Enrollment into AWARE cohorts1-4 have concluded and the primary objective and core goals for the study were met.
- |||||||||| Ibrance (palbociclib) / Pfizer
Biomarker, Trial completion date, Combination therapy, Circulating tumor DNA, Metastases: PADA-1: PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection (clinicaltrials.gov) - Aug 15, 2022 P3, N=1017, Active, not recruiting, Recruiting --> Terminated; Enrollment into AWARE cohorts1-4 have concluded and the primary objective and core goals for the study were met. Trial completion date: Apr 2024 --> Jun 2025
- |||||||||| Panel Participant (118C) - Aug 11, 2022 - Abstract #AHA2022AHA_2666;
Letrozole as a co-treatment drug in the IVF cycle of women with endometriosis can significantly reduce the gonadotropin dosage and estradiol level with the same pregnancy rates. There is no abstract associated with this presentation.
- |||||||||| letrozole / Generic mfg.
Coordination of CO2 adsorption capacity and metal electron cloud density to facilitate hydrogenation of CO2 to formate (Virtual-only (Zoom)) - Aug 9, 2022 - Abstract #ACSFall2022ACS_Fall_11086; At the same time, formic acid is a good hydrogen (H2) storage material with good application prospects.A novel covalent triazine framework CTF-L formed by the polymerization of letrozole was successfully synthesized through ionothermal method...The balance between the two can be harmonized to achieve the best activity of the catalyst.The best catalyst efficiently converted CO2 into formate through hydrogenation with a turnover number of 22000 after 1 h, being the highest reported to date for a heterogeneous catalyst, which makes it attractive toward industrial application. Furthermore, the synthesized catalyst was found to be stable in air and was recycled by simple filtration without significant loss of catalytic activity.
- |||||||||| metformin / Generic mfg., letrozole / Generic mfg.
Preclinical, Journal: The Improvement Effect of D-Chiro-Inositol and Ecklonia cava K. in the Rat Model of Polycystic Ovarian Syndrome. (Pubmed Central) - Aug 7, 2022 In rats with letrozole-induced PCOS, we focused on alternative therapies using EC and/or DCI extracts to alleviate ovarian failure...We divided 6-week-old female mice into the following six groups and evaluated them: vehicle, PCOS, PCOS + MET (metformin), PCOS + DCI, PCOS + EC, and PCOS + DCI + EC...These treatments also appeared to regulate the production of factors that affect follicle formation and inflammation in the ovaries. We concluded that EC extract and/or DCI administration influenced aromatase production and reduced LH and T stimulation, and cotreatment with EC and DCI consequently restored ovarian dysfunction or anti-inflammatory responses in rats with PCOS-like symptoms.
- |||||||||| Ibrance (palbociclib) / Pfizer
Trial completion date, Trial initiation date, Trial primary completion date, Liquid biopsy, Metastases, Biopsy: ICRG0201: Prediction of Treatment Efficacy of the Combination of Palbociclib/(Letrozole or Anastrozole) in First Line Metastatic Women With Luminal, HER2 Negative Advanced Breast Cancer, Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies. (clinicaltrials.gov) - Aug 4, 2022 P2, N=80, Not yet recruiting, Few recurrences were detected and unrelated to PBI. Trial completion date: Dec 2025 --> Apr 2026 | Initiation date: Jan 2022 --> Sep 2022 | Trial primary completion date: Dec 2022 --> Apr 2023
- |||||||||| letrozole / Generic mfg.
Trial completion date, Trial primary completion date: Controlled Ovarian Stimulation in Newly Diagnosed Breast Cancer PatiEnts (fAMHOPE) (clinicaltrials.gov) - Aug 4, 2022 P4, N=565, Recruiting, Trial completion date: Dec 2025 --> Apr 2026 | Initiation date: Jan 2022 --> Sep 2022 | Trial primary completion date: Dec 2022 --> Apr 2023 Trial completion date: Jan 2027 --> Jan 2029 | Trial primary completion date: Jan 2022 --> Dec 2023
- |||||||||| Rekovelle (follitropin delta) / Ferring
Journal: Fertility preservation for women with breast cancer: a multicentre randomized controlled trial on various ovarian stimulation protocols. (Pubmed Central) - Aug 4, 2022 Our study showed that adding tamoxifen or letrozole to a standard ovarian stimulation protocol in women with breast cancer does not impact the effectiveness of fertility preservation and paves the way for high-quality long-term follow-up on breast cancer treatment outcomes and women's future pregnancy outcomes. Our study also highlights the need for high-quality studies for all women opting for fertility preservation, as alternative ovarian stimulation protocols have been introduced to clinical practice without proper evidence.
- |||||||||| letrozole / Generic mfg.
Trial completion date: Brovale: Fertility Preservation in Breast Cancer Patients (clinicaltrials.gov) - Aug 3, 2022 P4, N=65, Active, not recruiting, Our study also highlights the need for high-quality studies for all women opting for fertility preservation, as alternative ovarian stimulation protocols have been introduced to clinical practice without proper evidence. Trial completion date: Dec 2022 --> Sep 2023
- |||||||||| letrozole / Generic mfg.
Preclinical, Journal: Short chain fatty acid, acetate restores ovarian function in experimentally induced PCOS rat model. (Pubmed Central) - Aug 3, 2022 His height is 168.7cm (-0.05SD) which is approaching his adult height after long-term treatment with letrozole, triptorelin, and spironolactone. Altogether, the present results suggest that acetate protects ovarian function with evidence of normal growing follicles and enhanced circulating 17-β estradiol by inhibition of HDAC.
- |||||||||| Phase classification, Enrollment change, Trial completion date, Trial primary completion date: STAPOVER: Signal TrAnsduction Pathway Activity Analysis in OVarian cancER (clinicaltrials.gov) - Aug 2, 2022
P2/3, N=148, Not yet recruiting, Altogether, the present results suggest that acetate protects ovarian function with evidence of normal growing follicles and enhanced circulating 17-β estradiol by inhibition of HDAC. Phase classification: P3 --> P2/3 | N=50 --> 148 | Trial completion date: Dec 2023 --> Oct 2026 | Trial primary completion date: Aug 2023 --> Oct 2025
- |||||||||| Herceptin (trastuzumab) / Roche, Kisqali (ribociclib) / Novartis, Perjeta (pertuzumab) / Roche
Trial completion date, Trial primary completion date: Detect V / CHEVENDO (Chemo vs. Endo) (clinicaltrials.gov) - Jul 28, 2022 P3, N=270, Recruiting, Trial primary completion date: Jun 2022 --> Dec 2022 Trial completion date: Jun 2023 --> Nov 2024 | Trial primary completion date: Sep 2021 --> Sep 2024
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD)
Debate Your Colleague 02: Optimal Treatment of Recurrent Low Grade Endometrial Cancer (Hall 501) - Jul 27, 2022 - Abstract #IGCS2022IGCS_339; Different approaches to treatment including chemotherapy, checkpoint inhibitor therapy, and combination therapy with pembrolizumab and lenvatanib will be discussed. The role of hormonal therapies (i.e.megesterol acetate, letrozole, etc) and hormonal combination therapies in the treatment of low grade endometrial cancer will be highlighted.
- |||||||||| 5-fluorouracil / Generic mfg., letrozole / Generic mfg., exemestane / Generic mfg.
Journal: Ursolic acid silences CYP19A1/aromatase to suppress gastric cancer growth. (Pubmed Central) - Jul 27, 2022 The docking simulation score of UA was compared with Ar inhibitors, e.g., letrozole, exemestane, in Ar protein crystallization...Together, the results indicate UA could be used to treat GCa by silencing Ar expression in GCa. Hedyotis diffusa Willd ethanol extract could be an functional food supplements.
|